• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Sanofi Genzyme Recognizes Rare Disease Day 2017 with Programs of Events around the World

    Sanofi Genzyme Recognizes Rare Disease Day 2017 with Programs of Events around the World

  2. Orthobiologics Market to Reach $10.2 Billion by 2025 - Driven by Increasing Orthopedic & Musculoskeletal Diseases Globally - Research and Markets

    Orthobiologics Market to Reach $10.2 Billion by 2025 - Driven by Increasing Orthopedic & Musculoskeletal Diseases Globally - Research and Markets

  3. Chinese Market Report for Anti-Adhesion Products - Research and Markets

    Chinese Market Report for Anti-Adhesion Products - Research and Markets

  4. Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016 - Research and Markets

    Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016 - Research and Markets

  5. Sanofi Seeks Cure for FDA Concerns at French Factory -- Update

    Sanofi Seeks Cure for FDA Concerns at French Factory -- Update

  6. ISS Endorses Full Slate of venBio Nominees at Immunomedics

    ISS Endorses Full Slate of venBio Nominees at Immunomedics

  7. Gaucher Disease - Pipeline Review, H2 2016 - Therapeutics Assessment by Drug Target, MoA, RoA & Molecule Type - Research and Markets

    Gaucher Disease - Pipeline Review, H2 2016 - Therapeutics Assessment by Drug Target, MoA, RoA & Molecule Type - Research and Markets

  8. Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016 - Research and Markets

    Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016 - Research and Markets

  9. Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors

    Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors

  10. X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease

    X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease

123

©2017 Morningstar Advisor. All right reserved.